Cargando…

Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results

BACKGROUND: Maintenance treatment after autologous bone marrow transplantation in multiple myeloma improves the outcome of patients. We designed a phase II clinical trial to evaluate the treatment with IL2 and zoledronate after autologous bone marrow transplantation in myeloma patients. METHODS: Pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fazzi, Rita, Petrini, Iacopo, Giuliani, Nicola, Morganti, Riccardo, Carulli, Giovanni, Dalla Palma, Benedetta, Notarfranchi, Laura, Galimberti, Sara, Buda, Gabriele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890401/ https://www.ncbi.nlm.nih.gov/pubmed/33613510 http://dx.doi.org/10.3389/fimmu.2020.573156

Ejemplares similares

PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients
por: Costa, Federica, et al.
Publicado: (2021)

CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents
por: Costa, Federica, et al.
Publicado: (2019)

Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation
por: Buda, Gabriele, et al.
Publicado: (2021)

Hematogones in patients with acute myeloid leukaemia: Prognostic value and correlation with minimal residual disease
por: Tavarozzi, Rita, et al.
Publicado: (2021)

Neurofibromatosis type I and multiple myeloma coexistence: A possible link?
por: Accardi, Fabrizio, et al.
Publicado: (2018)

Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma
por: Pacini, Simone, et al.
Publicado: (2019)

PRDI-BF1 and PRDI-BF1P isoform expressions correlate with disease status in multiple myeloma patients
por: Buda, Gabriele, et al.
Publicado: (2017)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

P58 LOW CD38 EXPRESSION BY PLASMA CELLS IN EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA PATIENTS
por: Notarfranchi, L., et al.
Publicado: (2023)

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
por: Accardi, Fabrizio, et al.
Publicado: (2015)

Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties
por: Costa, Federica, et al.
Publicado: (2017)

Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response
por: Storti, Paola, et al.
Publicado: (2022)

Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma
por: Romano, Alessandra, et al.
Publicado: (2021)

Joint Pain and Arthritis as First Clinical Manifestation of Systemic Amyloidosis and Multiple Myeloma: Case Report and Brief Literature Review
por: Mazziotta, Francesco, et al.
Publicado: (2022)

Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients
por: Marchica, Valentina, et al.
Publicado: (2019)

Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies
por: Storti, Paola, et al.
Publicado: (2020)

P850: THE HUMORAL AND CELLULAR RESPONSE TO SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA AND PRE-MALIGNANT MONOCLONAL GAMMOPATHIES: IMPACT OF OMICRON VARIANT
por: Storti, P., et al.
Publicado: (2022)

The CoV-2 outbreak: how hematologists could help to fight Covid-19
por: Galimberti, Sara, et al.
Publicado: (2020)

Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability
por: Chiu, Martina, et al.
Publicado: (2020)

A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis
por: Accardi, Fabrizio, et al.
Publicado: (2018)

Mesangiogenic Progenitor Cells Derived from One Novel CD64(bright)CD31(bright)CD14(neg) Population in Human Adult Bone Marrow
por: Pacini, Simone, et al.
Publicado: (2016)

Bone Marrow Monocyte / Macrophage Derived Activin A Mediates the Osteoclastogenic Effect of IL-3 in Multiple Myeloma
por: Silbermann, Rebecca, et al.
Publicado: (2013)

Are MSCs angiogenic cells? New insights on human nestin-positive bone marrow-derived multipotent cells
por: Pacini, Simone, et al.
Publicado: (2014)

IL21R expressing CD14(+)CD16(+) monocytes expand in multiple myeloma patients leading to increased osteoclasts
por: Bolzoni, Marina, et al.
Publicado: (2017)

Discordant lymphoma consisting of splenic mantle cell lymphoma and marginal zone lymphoma involving the bone marrow and peripheral blood: a case report
por: Carulli, Giovanni, et al.
Publicado: (2011)

Interference of Monoclonal Gammopathy with Fibrinogen Assay Producing Spurious Dysfibrinogenemia
por: Martini, Francesca, et al.
Publicado: (2019)

Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
por: Del Giudice, Maria Livia, et al.
Publicado: (2021)

Organ Stiffness in the Work-Up of Myelofibrosis and Philadelphia-Negative Chronic Myeloproliferative Neoplasms
por: Benedetti, Edoardo, et al.
Publicado: (2020)

P830: IDENTIFICATION OF NOVEL TARGET GENES CORRELATED WITH 1Q21 AMPLIFICATION IN PATIENTS WITH SMOLDERING MYELOMA AND MULTIPLE MYELOMA
por: Thomas Iannozzi, Nicolas, et al.
Publicado: (2023)

Autophagy and the Bone Marrow Microenvironment: A Review of Protective Factors in the Development and Maintenance of Multiple Myeloma
por: Hamedi, Kamron R., et al.
Publicado: (2022)

Different types of amyloid concomitantly present in the same patients
por: Martini, Francesca, et al.
Publicado: (2019)

High NESTIN Expression Marks the Endosteal Capillary Network in Human Bone Marrow
por: Panvini, Francesca M., et al.
Publicado: (2020)

Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells
por: Ubellacker, Jessalyn M., et al.
Publicado: (2017)

Single-Dose Therapy of Zoledronic Acid for the Treatment of Primary Bone Marrow Edema Syndrome
por: Vasiliadis, Angelo V, et al.
Publicado: (2021)

Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma
por: Manzoni, Martina, et al.
Publicado: (2020)

Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy
por: Marchica, Valentina, et al.
Publicado: (2020)

Prethymic Cytoplasmic CD3 Negative Acute Lymphoblastic Leukemia or Acute Undifferentiated Leukemia: A Case Report
por: Cannizzo, Elisa, et al.
Publicado: (2011)

Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study
por: Spencer, Andrew, et al.
Publicado: (2008)

Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report
por: Noriega Aldave, Adrian P, et al.
Publicado: (2014)

Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis
por: Kim, Hyung Joon, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_075h558memj2dk6oqar6slaf0d